Skip to main content
Fig. 4 | Orphanet Journal of Rare Diseases

Fig. 4

From: Annual severity increment score as a tool for stratifying patients with Niemann-Pick disease type C and for recruitment to clinical trials

Fig. 4

The inclusion criteria for three clinical trials were modeled on plots of age versus total severity score (minus hearing). a Miglustat trial, ages > 12; b Arimoclomol trial ages 2–18 and c 2-Hydroxy-beta-cyclodextrin ages 4–21. The plots depict the study cohort with these different inclusion criteria indicated with the dotted lines. Included patients are in black, excluded patients in white

Back to article page
\